PMID- 24684667
OWN - NLM
STAT- MEDLINE
DCOM- 20150526
LR  - 20171116
IS  - 1557-8577 (Electronic)
IS  - 1549-1684 (Linking)
VI  - 17
IP  - 4
DP  - 2014 Aug
TI  - Potential of birds to serve as pathology-free models of type 2 diabetes, part 2: 
      do high levels of carbonyl-scavenging amino acids (e.g., taurine) and low 
      concentrations of methylglyoxal limit the production of advanced glycation 
      end-products?
PG  - 347-58
LID - 10.1089/rej.2014.1561 [doi]
AB  - In our previous publication, we reported on the advantages of using birds as a 
      pathology-free model of type 2 diabetes mellitus (T2DM). Using this new 
      perspective, we observed that birds are missing the RAGE gene, considered an 
      important factor in the development of diabetic complications. In this article, 
      we identify two additional Maillard reaction-related characteristics of birds 
      that have the potential to account, in part, for avian ability to cope 
      successfully with chronic hyperglycemia. First, compared to mammals, blood plasma 
      of birds has significantly higher concentrations of taurine and other free amino 
      acids that act as scavengers of reactive carbonyls. Second, there are also 
      indications that avian blood plasma contains lower concentrations of 
      methylglyoxal (MG) due, in part, to its decreased production by avian 
      erythrocytes. Our deductions are based on relatively meager experimental data and 
      are therefore speculative. One certain outcome of our study, however, is the idea 
      that birds can be a useful model for the study of Maillard reactions and etiology 
      of diabetic complications. We anticipate and hope that results of future studies 
      will support the hypothesis identifying MG as a key intermediate in the etiology 
      of diabetic complications. If this is indeed the case, then prevention and 
      control of diabetic complications may become transformed into a more 
      circumscribed, defined, and tractable problem whose goals will be to minimize the 
      production of MG and to maximize its elimination by detoxification or scavenging.
FAU - Szwergold, Benjamin S
AU  - Szwergold BS
AD  - Deglycation Research Inc. , West Lebanon, New Hampshire.
FAU - Miller, Craig B
AU  - Miller CB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Rejuvenation Res
JT  - Rejuvenation research
JID - 101213381
RN  - 0 (Albumins)
RN  - 0 (Glycation End Products, Advanced)
RN  - 1EQV5MLY3D (Taurine)
RN  - 4429-04-3 (Fructosamine)
RN  - 722KLD7415 (Pyruvaldehyde)
RN  - 94ZLA3W45F (Arginine)
RN  - BJ4I2X2CQJ (pentosidine)
RN  - IY9XDZ35W2 (Glucose)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
MH  - Albumins/chemistry
MH  - Animals
MH  - Arginine/analogs & derivatives/chemistry
MH  - Birds
MH  - Diabetes Mellitus, Type 2/*physiopathology
MH  - *Disease Models, Animal
MH  - Fructosamine/blood/chemistry
MH  - Glucose/chemistry
MH  - Glycation End Products, Advanced/*blood
MH  - Lysine/analogs & derivatives/chemistry
MH  - Maillard Reaction
MH  - Pyruvaldehyde/blood
MH  - Taurine/blood
EDAT- 2014/04/02 06:00
MHDA- 2015/05/27 06:00
CRDT- 2014/04/02 06:00
PHST- 2014/04/02 06:00 [entrez]
PHST- 2014/04/02 06:00 [pubmed]
PHST- 2015/05/27 06:00 [medline]
AID - 10.1089/rej.2014.1561 [doi]
PST - ppublish
SO  - Rejuvenation Res. 2014 Aug;17(4):347-58. doi: 10.1089/rej.2014.1561.